Update on Affibody molecules for in vivo imaging of targets for cancer therapy

V. Tolmachev, A. Orlova

Research output: Contribution to journalReview articlepeer-review

11 Citations (Scopus)


An increasing specificity of the cancer treatment requires an accurate detection of cancer-associated molecular targets to avoid over- and undertreatment. Radionuclide molecular imaging is a promising way for visualisation of such targets. Affibody molecules (Affibody® molecules), small (7 kDa) robust scaffold proteins constitute a new promising class of high-affinity molecular probes for in vivo molecular imaging. Pre-clinical studies demonstrated a great potential of derivatives of 2HER2:342 Affibody molecule to visualise expression of HER2 in tumour xenografts. Robustness of the Affibody scaffold enabled labelling in harsh conditions without loosing specificity of the HER2-binding. This paper provides an overview of the recent development of Affibody molecules. During the recent year, an important achievement was the development of site-specific labelling of Affibody molecules providing well-characterised uniform conjugates with defined biodistribution and targeting properties. The site-specific labelling was obtained either by an incorporation of chelators during peptides synthesis of Affibody molecules or by an introduction of a single cysteine in the originally cysteine-free Affibody scaffold and the use of a thiol-directed coupling. A feasibility of modification of the biodistribution of Affibody molecules by different chelators was another interesting finding. This was demonstrated during development of mercaptoacetyl-containing peptide based chelators for 99mTc-labelling of Affibody molecules. Several positron-emitting labels enabled the use of advantages of PET for Affibody-mediated radionuclide imaging. It was demonstrated that the rapid targeting of Affibody molecules is compatible with the use of such labels as 68Ga and 18F.

Original languageEnglish
Pages (from-to)21-30
Number of pages10
JournalMinerva Biotecnologica
Issue number1
Publication statusPublished - Mar 2009
Externally publishedYes


  • Affibody molecules
  • HER2
  • Neoplams
  • Radionuclide imaging
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Fingerprint Dive into the research topics of 'Update on Affibody molecules for in vivo imaging of targets for cancer therapy'. Together they form a unique fingerprint.

Cite this